ReviewBiomarkers in cancer2015
Biomarkers of Angiogenesis in Colorectal Cancer.
Review in Biomarkers in cancer, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It is linked to trial NCT06115174 (Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer), which is not on this map. Cited by 62 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Clinical Study Evaluating the Anticancer Effect of Pentoxiphylline in Patients With Metastatic Colorectal Cancer
Who cites it
62 citing papers in PubMed, 84 citations in OpenAlex.
- Trial
- Inflammation- and angiogenesis-related biomarkers are correlated with cancer-related fatigue in colorectal cancer patients: Results from the ColoCare Study.European journal of cancer care · 2019Trial
- Globo-H diagnostic stratification and identification of DUSP14 as a candidate target in colorectal cancer.International journal of cancer · 2026Article
- The Current Role of Antiangiogenics in Colorectal Cancer.International journal of molecular sciences · 2025Review
- Gene Expression-Based Inference of Metabolic Signatures Reveals Distinct Molecular Profiles in Right- and Left-Sided Colon Cancer.Metabolites · 2025Article
- Associations of Biomarkers of Systemic Inflammation, Angiogenesis, and Cell-to-Cell Adhesion With Tumor Budding Among Early-Onset and Later-Onset Colorectal Cancer Patients.Cancer medicine · 2025Observational
- Gold nanocomposites in colorectal cancer therapy: characterization, selective cytotoxicity, and migration inhibition.Naunyn-Schmiedeberg's archives of pharmacology · 2025Article
- A machine learning-derived angiogenesis signature for clinical prognosis and immunotherapy guidance in colon adenocarcinoma.Scientific reports · 2025Article
- Review
- Brucea javanica oil emulsion plus supportive care for refractory advanced colorectal cancer: a pilot RCT protocol.Frontiers in pharmacology · 2025Article
- Analyzing the Functional Roles and Immunological Features of Chemokines in COAD.International journal of molecular sciences · 2024Article
- Genistein-Aspirin Combination Exerts Cytotoxic and Anti-Migratory Effects in Human Colorectal Cancer Cells.Life (Basel, Switzerland) · 2024Article
- Review
- Real-World Outcomes of First-Line FOLFIRI Plus Bevacizumab with Irinotecan Dose Escalation versus FOLFOXIRI Plus Bevacizumab inMedicina (Kaunas, Lithuania) · 2023Observational
- Exosomal circCOL1A1 promotes angiogenesis via recruiting EIF4A3 protein and activating Smad2/3 pathway in colorectal cancer.Molecular medicine (Cambridge, Mass.) · 2023Article
- The emergence of RAS mutations in patients with RAS wild-type mCRC receiving cetuximab as first-line treatment: a noninterventional, uncontrolled multicenter study.British journal of cancer · 2023Article
- Dysregulated Forkhead Box (FOX) Genes Association with Survival Prognosis, Anti-tumor Immunity, and Key Targeting Drugs in Colon Adenocarcinoma.Archives of Iranian medicine · 2023Article
- Overcoming the Challenges of Phytochemicals in Triple Negative Breast Cancer Therapy: The Path Forward.Plants (Basel, Switzerland) · 2023Review
- The Roles of Zinc Finger Proteins in Colorectal Cancer.International journal of molecular sciences · 2023Review
- Pre-Surgery Inflammatory and Angiogenesis Biomarkers as Predictors of 12-Month Cancer-Related Distress: Results from the ColoCare Study.Cancer epidemiology, biomarkers & prevention : a publication of the American Association for Cancer Research, cosponsored by the American Society of Preventive Oncology · 2023Article
2 more citing papers are in PubMed but not listed here.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors at 1 institution in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Colorectal cancer (CRC) is the third most common cancer worldwide and accounts for 10% of all new cancer diagnoses. Angiogenesis is a tightly regulated process that is mediated by a group of angiogenic factors such as vascular endothelial growth factor and its receptors. Given the widespread use of antiangiogenic agents in CRC, there has been considerable interest in the development of methods to identify novel markers that can predict outcome in the treatment of this disease with angiogenesis inhibitors. Multiple biomarkers are in various phases of development and include tissue, serum, and imaging biomarkers. The complexity of the angiogenesis pathway and the overlap between the various angiogenic factors present a significant challenge to biomarker discovery. In our review, we discuss the angiogenesis pathway and the most promising evolving concepts in biomarker discovery, as well as highlight the landmark studies that identify subgroups of patients with CRC who may preferentially benefit from angiogenesis inhibitors.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.